Medicare AdvantageCoverageMedium impact
MA08.086d, Nusinersen (Spinraza®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Oct 2, 2024
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.086d for Nusinersen (Spinraza®) has been reissued and updated. This affects coverage and billing requirements for this spinal muscular atrophy treatment under Medicare Advantage plans.
Action Required
Immediately: Review updated MA08.086d policy for Nusinersen (Spinraza®) coverage requirements. Billing team must verify current prior authorization, coverage criteria, and documentation requirements for Medicare Advantage patients receiving this treatment. Update billing protocols and staff training accordingly to ensure compliance with the reissued policy effective October 2024.